Stock listing
NASDAQ:TBIO Translate Bio Inc Stock
Follow Translate Bio Inc into a list and get an email when it puts out news.
Last close · NASDAQ:TBIO
$37.36 USD
Close on Sep 14, 2021 · No longer trades
- Lowest – highest close
- $4.90 – $37.85 USDSince Jun 28, 2018 · lowest Jan 22, 2019 · highest Aug 4, 2021
Delisted NASDAQ:TBIO no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:TBIO
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Translate Bio Inc on 6ix
- Decks
- 2 decks · latest Aug 25, 2020
Events
| Quarter | Results |
|---|---|
| Quarter to Sep 30, 2024 | Nov 11, 2024 · Before open |
| Quarter to Jun 30, 2024 | Aug 7, 2024 · After close |
| Quarter to Mar 31, 2024 | May 9, 2024 · After close |
| Quarter to Dec 31, 2023 | Mar 28, 2024 · After close |
| Quarter to Sep 30, 2023 | Nov 13, 2023 · After close |
| Quarter to Jun 30, 2023 | Aug 10, 2023 · After close |
| Quarter to Mar 31, 2023 | May 11, 2023 · After close |
| Quarter to Dec 31, 2022 | Mar 21, 2023 · After close |
| Quarter to Sep 30, 2022 | Nov 8, 2022 · After close |
| Quarter to Jun 30, 2022 | Aug 9, 2022 · After close |
All 16 quarters
| Quarter | Results |
|---|---|
| Quarter to Mar 31, 2022 | May 10, 2022 · After close |
| Quarter to Dec 31, 2021 | Mar 22, 2022 · After close |
| Quarter to Sep 30, 2021 | Nov 9, 2021 · After close |
| Quarter to Jun 30, 2021 | Aug 10, 2021 · After close |
| Quarter to Mar 31, 2021 | Jun 21, 2021 · Before open |
| Quarter to Dec 31, 2020 | Feb 25, 2021 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (August 2020) | Technical | 8 slides | Aug 25, 2020 |
| Investor Presentation (January 2020) | Investor deck | 25 slides | Jan 13, 2020 |
Cap table
Built by 6ix from Translate Bio Inc’s releases
- Common shares
- 1,775,839
- Fully diluted
- 1,775,839
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,775,839 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,775,839 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jean-François Formela Other companies: Korro Bio, Inc. (Co-Founder & Director · Since at least Nov 3, 2023); ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 7, 2024 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Oruka Therapeutics, Inc. (Director · Feb 10, 2012 – Oct 22, 2012 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past) | Director · Jun 27, 2018 – Sep 14, 2021 · Past |
| Daniella Beckman Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past) | Director · Jun 18, 2019 – Sep 14, 2021 · Past |
| Brian M Gallagher Jr Other companies: eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Rein Therapeutics, Inc. (Director · Jun 28, 2017 – Jul 25, 2017 · Past) | Director · Jun 27, 2018 – Jul 2, 2018 · Past |
| Paul Burgess Other companies: Kailera Therapeutics, Inc. (Chief Operating Officer & Chief Business Officer · Since at least Apr 16, 2026); Cerevel Therapeutics Holdings Inc (See Remarks · Jun 20, 2023 – Aug 1, 2024 · Past) | General Counsel and Secretary · Jun 27, 2018 – Jun 27, 2018 · Past |
| Robert Plenge Other companies: BioMarin Pharmaceutical Inc. (Director · Since at least Sep 10, 2026); Bristol-Myers Squibb Company (EVP, Chief Research Officer · Since at least Jul 3, 2023) | Director · Jun 16, 2021 – Sep 14, 2021 · Past |
| Ann Barbier Other companies: Palvella Therapeutics, Inc. (Director · Apr 24, 2018 – Jun 21, 2023 · Past) | Chief Medical Officer · Jun 27, 2018 – Mar 9, 2021 · Past |
| Brendan Smith Other companies: CRISPR Therapeutics AG (Chief Financial Officer · Oct 14, 2021 – Feb 18, 2023 · Past) | Chief Financial Officer · Apr 19, 2021 – Sep 14, 2021 · Past |
| Brian Fenton | Chief Business Officer · Jun 27, 2018 – Mar 8, 2019 · Past |
Log in to ask 6ix AI your own questions about Translate Bio Inc.